Back to top
more

Cerecor Inc. (CERC)

(Delayed Data from NSDQ)

$5.57 USD

5.57
25,261

+0.13 (2.39%)

Updated May 3, 2019 04:00 PM ET

After-Market: $5.56 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

Avalo Therapeutics, Inc. [CERC]

Reports for Purchase

Showing records 1 - 20 ( 55 total )

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/22/2021

Company Report

Pages: 4

Placing Rating and PT Under Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

08/13/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/19/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/13/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/02/2019

Company Report

Pages: 5

Pediatric Portfolio Sale Removes Debt Overhang; Raising Target to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/21/2019

Company Report

Pages: 4

CERC-802 Receives Fast Track Designation From FDA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/12/2019

Company Report

Pages: 5

2Q19 Financial Results Reported; Slight Revenue Miss, But Guidance Maintained; Bottom-Line Beat; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

07/30/2019

Company Report

Pages: 4

CERC-802 Investigational New Drug Application Accepted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/23/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

07/15/2019

Company Report

Pages: 4

Key Natural History Study in Ultra-Rare Congenital Disorders of Glycosylation Starts Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

07/02/2019

Industry Report

Pages: 12

Surveying the Parkinson''s Disease Treatment Continuum: KOL Conference Call Recap

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/02/2019

Company Report

Pages: 4

CERC-301 Final Phase 1 Results Underscore Promise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/28/2019

Company Report

Pages: 4

1Q19 Financial Results Reported; Sales Exceed Expectations; Multiple Catalysts Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/13/2019

Company Report

Pages: 8

Price: 24.95

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

04/29/2019

Company Report

Pages: 4

CERC-801 Phase 1 Dosing Completion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

04/17/2019

Company Report

Pages: 4

Positive Interim CERC-301 Phase 1 Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/17/2019

Company Report

Pages: 6

Price: 24.95

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/15/2019

Company Report

Pages: 5

Leadership Transition Unlikely to Affect Trajectory; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/01/2019

Company Report

Pages: 41

Melding a Commercial Platform With Ultra-Rare Drug Development; Initiating at Buy and $11 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 100.00

Research Provided by a Third Party

Company: Avalo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/26/2019

Company Report

Pages: 10

Price: 24.95

// eof